Fig 1.
Flow chart indicates the selection of studies.
RCT = randomized clinical trial.
Fig 2.
Consensus risk of bias assessments of the included studies.
Green: Low risk, Yellow: Unclear, Red: High risk.
Table 1.
Characteristics of eligible RCTs included in this meta-analysis.
Fig 3.
Forest plot of the (A) ORR and (B) one-year survival in patients with NSCLC randomly assigned to COX-2 inhibitors treatment versus placebo/no intervention.
ORR = overall response rate.
Table 2.
Main ORR and survival results extracted from the included RCTs.
Table 3.
Meta-analysis of ORR and one-year Survival in subgroups on the basis of Cox-2 inhibitor, treatment line, and treatment protocol.
Table 4.
Meta-analysis of the toxicities in patients with cancer randomly assigned to celecoxib or placebo/no intervention.
Fig 4.
Funnel plot of risk ratio for studies included in the meta-analysis.
analysis. (A)ORR, P = 0.43, Egger’s test; (B) one-year survival, P = 0.297, Egger’s test. ORR = overall response rate.